In his role as Senior Vice President, Philadelphia Project Operations at DPS, Ryan leads the strategic direction and continued growth of the Philadelphia office, with a focus on expanding its client base and driving project operations improvements. He’s responsible for sales and marketing of DPS Philadelphia’s services, including architectural and engineering design, commissioning, qualification, and validation (CQV), and construction management.
Maya Yovcheva is an R&D scientist with more than ten years of experience in cell biology, protein expression, and product development. She has been a product development scientist at Thermo Fisher Scientific for six years, developing novel tools and platforms for protein expression and viral vector production. Her work has led to the launch of a new platform for baculovirus-based protein expression in insect cells. Maya holds a bachelor’s degree in Molecular Biology and a Master’s degree in Medical Biotechnology.
Sandy is the President and Founder of Access Biomedical Solutions, a consultancy launched in 2015 that is focused on empowering biotech and medtech companies grow and accomplish their goals. She achieves this by combining her technical expertise and marketing skills to quickly identify a company’s current trajectory, what success looks like for them, and what their biggest gaps are.
A serial entrepreneur and ecosystem builder, Julie Lenzer is currently the Chief Innovation Officer at the University of Maryland and Founding Director for the newly-launched Quantum Startup Foundry. In these roles, she is charged with fostering and deploying innovation to drive economic and social impact from both university-affiliated and community-based innovators and oversees the university’s tech transfer office, the Maryland Small Business Development Center (SBDC), the Veteran’s Business Outreach Center (VBOC), the Mixed/Augmented/Virtual Reality Innovation Center (MAVRIC), as well as university engagement with the Discovery District (UMD’s 150-acre research park). An active angel investor, she is also on the investment committee of the $10M Maryland Momentum Fund and UMD’s newly-launched Discovery Fund.
Dr. Fussell represents a diverse array of clients in various intellectual property matters, including patent and trademark prosecution and litigation. She performs due diligence, freedom-to-operate, validity, and patentability analyses in the chemical and life sciences industries. She has a wide range of experience in the biotechnology, pharmaceutical, and chemical arts, including medical devices, biofuels, probiotics, plants, herbicides, fertilizers, seeds, nucleic acids, proteins, enzymes, carbohydrates, diagnostics, methods of treating cancer, cancer diagnostics, and agents for treating cancer. Dr. Fussell has negotiated and drafted a wide variety of agreements relating to intellectual property interests, including settlement agreements.
5 Questions with Eric A. Stahlberg, PhD, Director Bioinformatics and Data Science, Frederick National Laboratory for Cancer Research
Dr. Eric Stahlberg is director of Biomedical Informatics and Data Science at the Frederick National Laboratory for Cancer Research (FNL). Stahlberg has been instrumental in establishing FNL’s high-performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology.
Dr. Kayla Valdes is a Senior Manager at Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare diseases. Prior to joining Horizon, Dr. Valdes worked at the National Institutes of Health as a Senior Program Manager on the Cure Sickle Cell Initiative. She was also the Associate Director of Scientific Programs at the Drug Information Association (DIA), where she developed DIA’s global content strategy by providing scientific expertise in therapeutic drug development and regulatory policy.
Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 25 years of institutional investment experience.
Dr. Hasan is a molecular microbiologist specialized in genomics, microbiome R&D, and strategic development of technology innovation in the biotech and life science industries. His work has resulted in multiple patents and hundreds of peer-reviewed articles, abstracts, and conference proceedings in the field of microbial genomics, microbiome, molecular ecology, and infectious diseases.
Jacque Myers has 15 years of experience working across the health ecosystem, specializing in evidence-based communications to promote healthy behaviors and advance large-scale business transformations. She has focused on digital health acceleration for the last six years, including connected health, workflow automation, and research dissemination and implementation.